Creon pancrelipase: Phase III data

A double-blind, crossover, U.S. Phase III trial in 16 patients ages 7-11 with pancreatic exocrine insufficiency due to CF showed that Creon met the primary endpoint of significantly improving fat absorption as measured by the mean coefficient of fat absorption (CFA) compared with placebo at 5 days (82.8% vs. 47.4%, p<0.001). Data were presented at the North American Cystic Fibrosis meeting in Minneapolis. ...